US05380C1027 - Common Stock
AVITA MEDICAL INC
NASDAQ:RCEL (5/3/2024, 7:15:02 PM)
After market: 8.76 +0.01 (+0.11%)8.75
+0.03 (+0.34%)
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California. The company went IPO on 2012-03-18. The firm is engaged in the development and commercialization of devices and autologous cellular therapies for skin restoration. The Company’s RECELL System is a single use (disposable), stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells necessary to regenerate natural healthy epidermis. These Spray-On Skin Cells are prepared at the point of care, providing a new way to treat thermal burns, other wounds, skin injuries or defects of the skin. The RECELL System is designed to be used at the point of care alone or in combination with autografts, depending on the depth of the burn injury.
AVITA MEDICAL INC
28159 Avenue Stanford, Suite 220
Valencia California CALIFORNIA 91355
P: 16613679170
CEO: Michael Perry
Employees: 0
Website: https://www.avitamedical.com/
AVITA Medical will report first quarter 2024 financial results after the close on May 13, 2024, and host a webcast that day at 1:30 p.m. Pacific Time. ...
AVITA Medical updates expected Q1 2024 commercial revenue; reaffirms expectations for full-year 2024 revenue at lower end of previously provided guidance....
Here you can normally see the latest stock twits on RCEL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: